According to a story in Time magazine, representatives at Bristol Myers Squibb note that for individuals without insurance coverage, a monthly supply of Cobenfy will likely cost around $1,850, but “could” be lower for those who are insured. Schizophrenia is a chronic mental health disorder that can lead to disability, significantly impacting a person’s quality of life. Its symptoms can also often be highly personalized, meaning one drug or treatment may not work for every affected individual. Due to the side effects of older antipsychotic drugs, medication adherence has remained a real issue when it comes to treating this condition, which is why the FDA’s approval of Cobenfy has been so celebrated by experts. However, no medication—especially one that has only recently been approved—comes without side effects. As Cobenfy’s rollout continues this fall, it will be necessary for both physicians and patients to watch out for both expected and unexpected reactions.